Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial

2020199 citationsJournal Articlebronze Open Access

Authors

Aimée R. Kreimer · National Cancer Institute

Joshua N. Sampson · National Cancer Institute

Carolina Porras · Instituto Costarricense de Investigación y Enseñanza en Nutrición y Salud

John T. Schiller · National Cancer Institute

Troy J. Kemp · Frederick National Laboratory for Cancer Research

Rolando Herrero · Centre International de Recherche sur le Cancer

Sarah Wagner

Abstract

More than a decade after HPV vaccination, single-dose VE against HPV16 or 18 infection remained high and HPV16 or 18 antibodies remained stable. A single dose of bivalent HPV vaccine may induce sufficiently durable protection that obviates the need for more doses.

Topics & Keywords

Cervical Cancer and HPV Research Hepatitis B Virus Studies Microbial infections and disease research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JNCI Journal of the National Cancer Institute

Volume 112, Issue 10, pp. 1038-1046

DOI: 10.1093/jnci/djaa011

Field-Weighted Citation Impact: 12.66